May 20, 2020 / 7:03 AM / 15 days ago

BRIEF-Astrazeneca Receives Lynparza Approval In The US For Prostate Cancer

May 20 (Reuters) - AstraZeneca PLC:

* LYNPARZA APPROVED IN THE US FOR PROSTATE CANCER

* APPROVED IN US FOR PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

* APPROVAL BY FOOD AND DRUG ADMINISTRATION WAS BASED ON RESULTS FROM PHASE III PROFOUND TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below